Adaptive pathways: Possible next steps for payers in preparation for their potential implementation

Frontiers in Pharmacology

Volumn 8, Issue AUG, 2017, Pages

  Bonanno, Patricia Vella ^a   Ermisch, Michael ^b   Godman, Brian ^a,c,d   Martin, Antony P ^c   Van Den Bergh, Jesper ^e   Bezmelnitsyna, Liudmila ^f   Bucsics, Anna ^g   Arickx, Francis ^h   Bybau, Alexander ⁱ   Bochenek, Tomasz ^j   van de Casteele, Marc ^h   Diogene, Eduardo ^k   Eriksson, Irene ^d,l   Fürst, Jurij ^m   Gad, Mohamed ⁿ   Greičiute Kuprijanov, Ieva ^o   van der Graaff, Martin ^p   Gulbinovic, Jolanta ^q,r   Jones, Jan ^s   Joppi, Roberta ^t   Kalaba, Marija ^u   Laius, Ott ^v   Langner, Irene ^w   Mardare, Ileana ^x   Markovic Pekovic, Vanda ^y,z   Magnusson, Einar ^aa   Melien, Oyvind ^ab   Meshkov, Dmitry O ^e   Petrova, Guenka I ^ac   Selke, Gisbert ^w   Sermet, Catherine ^ad   Simoens, Steven ^ae   Schuurman, Ad ^p   Ramos, Ricardo ^af   Rodrigues, Jorge ^af   Zara, Corinne ^ag   Zebedin Brandl, Eva ^ah   Haycox, Alan ^c   more..

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b National Association of Statutory Health Insurance Funds   (Germany)

^c UNIVERSITY OF LIVERPOOL MANAGEMENT SCHOOL   (United Kingdom)

^d KAROLINSKA INSTITUTE   (Sweden)

^e ECORYS Netherlands   (Netherlands)

^f N A SEMASHKO NATIONAL RESEARCH INSTITUTE OF PUBLIC HEALTH   (Russian Federation)

^g Mechanism of Coordinated Access to Orphan Medicinal Products (MoCA)   (Belgium)

^h National Institute for Health and Disability Insurance   (Belgium)

ⁱ Zilveren Kruis Achmea ^*  (Netherlands)

^j JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^k HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^l STOCKHOLM COUNTY COUNCIL   (Sweden)

^m Health Insurance Institute of Slovenia   (Slovenia)

ⁿ IMPERIAL COLLEGE LONDON   (United Kingdom)

^o Ministry of Health of the Republic of Lithuania   (Lithuania)

^p National Health Care Institute (ZIN)   (Netherlands)

^q VILNIUS UNIVERSITY   (Lithuania)

^r State Medicine Control Agency of Lithuania   (Lithuania)

^s Scottish Medicines Consortium   (United Kingdom)

^t Clinical Research and Drug Assessment Unit   (Italy)

^u Clinical centre Zemun   (Serbia)

^v State Agency of Medicines   (Estonia)

^w Wissenschaftliches Institut der AOK   (Germany)

^x CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^y MINISTRY OF HEALTH AND SOCIAL WELFARE   (Bosnia and Herzegovina)

^z UNIVERSITY OF BANJA LUKA   (Bosnia and Herzegovina)

^aa Ministry of Health   (Iceland)

^ab Norwegian Directorate for Health   (Norway)

^ac MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^ad Institut de Recherche et Documentation en Economie de la Santé IRDES   (France)

^ae UNIVERSITY OF LEUVEN   (Belgium)

^af INFARMED)   (Portugal)

^ag C Agy Hlth Technol Assess Res   (Spain)

^ah Main Assoc Austrian Social Ins I   (Austria)

more..

Author keywords

Adaptive Pathways; European Medicines Agency; Health Technology Assessment; Marketing authorization; Payers

Indexed keywords

BIOMEDICAL TECHNOLOGY ASSESSMENT; EUROPEAN MEDICINES AGENCY; FUNDING; HUMAN; INFORMATION PROCESSING; MARKETING; MEDICINE; MONITORING; UNCERTAINTY;

EID: 85028309648     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2017.00497     Document Type: Review

References (118)

1. Adamski, J., Godman, B., Ofierska-Sujkowska, G., Osinska, B., Herholz, H., Wendykowska, K., et al. (2010). Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv. Res. 10:153. doi: 10.1186/1472-6963-10-153
2. Aggarwal, A., Fojo, T., Chamberlain, C., Davis, C., and Sullivan, R. (2017) Do patient access schemes for high-cost cancer drugs deliver value to society? -lessons from the NHS Cancer Drugs Fund. Ann. Oncol. doi: 10.1093/annonc/mdx110. [Epub ahead of print].
3. ANSM (2015). Notice to Applicants for Marketing for Temporary Authorisation for Use (ATU). Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM). Available online at: http://ansm.sante.fr/var/ansm_site/storage/ original/application/cadfbcf9594614d59c8915670853a28b.pdf
4. Aronson, J. K., Ferner, R. E., and Hughes, D. A. (2012). Defining rewardable innovation in drug therapy. Nat. Rev. 11, 253-254. doi: 10.1038/nrd3715
5. Avorn, J. (2015). The $2.6 billion pill - methodologic and policy considerations. N. Engl. J. Med. 372, 1877-1879. doi: 10.1056/NEJMp1500848
6. Banzi, R., Gerardi, C., Bertele, V., and Garattini, S. (2015). Approvals of drugs with uncertain benefit-risk profiles in Europe. Eur. J. Intern. Med. 26, 572-584. doi: 10.1016/j.ejim.2015.08.008
7. Barrett, A., Roques, T., Small, M., and Smith, R. D. (2006). How much will Herceptin really cost? BMJ 333, 1118-1120. doi: 10.1136/bmj.39008.624051.BE
8. Bentley, T. G., Cohen, J. T., Elkin, E. B., Huynh, J., Mukherjea, A., Neville, T. H., et al. (2017). Validity and reliability of value assessment frameworks for new cancer drugs. Value Health 20, 200-205. doi: 10.1016/j.jval.2016.12.011
9. Bubela, T.,McCabe, C., Archibald, P., Atkins, H., Bradshaw, S. E., Kefalas, P., et al. (2015). Bringing regenerative medicines to the clinic: the future for regulation and reimbursement. Regen. Med. 10, 897-911. doi: 10.2217/rme.15.51
10. Cattarin, F. (2016). When Drug Approval is Quick, It Should Not Be Dirty. BEUC The European Consumer Organisation. 25/07/2016. Available online at: http://www.beuc.eu/blog/when-drug-approval-is-quick-it-should-not-be-dirty/
11. Cheng, S., McDonald, E. J., Cheung, M. C., Arciero, V. S., Qureshi, M., Jiang, D., et al. (2017). Do the American Society of Clinical Oncology Value Framework and the European Society of Medical Oncology Magnitude of Clinical Benefit Scale Measure the same construct of clinical benefit? J. Clin. Oncol. Jco2016716894. doi: 10.1200/jco.2016.71.6894. [Epub ahead of print].
12. Cohen, P., and Felix, A. (2014). Are payers treating orphan drugs differently? J. Market Access Health Policy 2:23513. doi: 10.3402/jmahp.v2.23513
13. Commission of the European Communities (2008). Safe, Innovative and Accessible Medicines: a Renewed Vision for the Pharmaceutical Sector. Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions.COM (2008) 666 final. Available online at: http://ec.europa.eu/transparency/regdoc/ rep/1/2008/EN/1-2008-666-EN-F1-1.Pdf
14. Council of the EU (2016). Council Conclusions on Strengthening the Balance in the Pharmaceutical Systems in the EU and its Member States. Available online at: http://www.consilium.europa.eu/en/press/press-releases/2016/06/ 17-epsco-conclusions-balance-pharmaceutical-system/
15. Crown,W., Buyukkaramikli, N., Thokala, P.,Morton, A.,Mustafa, Y.,Marshall, D. A., et al. (2017). Constrained optimization methods in health services research - an introduction: Report 1 of the ISPOR Optimization Methods emerging good practices task force. Value Health 20, 301-319. doi: 10.1016/j.jval.2017.01.013
16. Culyer, J. (1993). Equity and equality in health and healthcare. J. Health Econ. 12, 431-457. doi: 10.1016/0167-6296(93)90004-X
17. Davis, C., Lexchin, J., Jefferson, T., Gøtzsche, P., and McKee, M. (2016). "Adaptive pathways" to drug authorisation: adapting to industry? Br. Med. J. 354:i4437. doi: 10.1136/bmj.i4437
18. de Block, M. (2015). The Grand Duchy of Luxemburg Joins Belgium-Netherlands Initiative on Orphan Drugs. Press Communication, 24 September 2015. Available online at: http://www.deblock.belgium.be/fr/grand-duchyluxemburg-joins-belgium-netherlands-initiative-orphan-drugs
19. de Bruijn, W., Ibanez, C., Frisk, P., BakPedersen, H., Alkan, A., Vella Bonanno, P., et al. (2016). Introduction and utilisation of high priced HCV medicines across Europe; Implications for the future. Front. Pharmacol. 7:197. doi: 10.3389/fphar.2016.00197
20. Dimitrova, M., Petrova, G., Manova, M., Savova, A., Yancheva, N., Cervenjakova, T., et al. (2013). Economic impact of the highly active antiretroviral pharmacotherapy on cost and HIV/AIDS control in Bulgaria. Biotechnol. Biotechnol. Equip. 27, 3599-3604. doi: 10.5504/BBEQ.2012.0076
21. Eguale, T., Buckeridge, D., Verma, A., Winslade, N. E., Benedetti, A., Hanley, J. A., et al. (2016). Association of off-label drug use and adverse drug events in an adult population. JAMA Intern. Med. 176, 55-63. doi: 10.1001/jamainternmed.2015.6058
22. Eichler, H. G., Baird, L. G., Barker, R., Bloechl-Daum, B., Borlum-Kristensen, F., Brown, J., et al. (2015). From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients. Clin. Pharmacol. Ther. 97, 234-246. doi: 10.1002/cpt.59
23. Eichler, H. G., Bloechi-Daum, B., Brasseur, D., Breckenridge, A., Leufkens, H., Raine, J., et al. (2013). The risks of risk aversion in drug regulation. Nat. Rev. Drug Discov. 12, 907-916. doi: 10.1038/nrd4129
24. Eichler, H. G., Oye, K., Baird, L. G., Abadie, E., Brown, J., and Drum, C. L. (2012). Adaptive licensing: taking the next step in the evolution of drug approval. Clin. Pharmacol. Ther. 91, 426-437. doi: 10.1038/clpt.2011.345
25. Ermisch, M., Bucsics, A., Vella Bonanno, P., Arickx, F., Bybau, A., Bochenek, T., et al. (2016). Payers' views of the changes arising through the possible adoption of Adaptive Pathways. Front. Pharmacol. 7:305. doi: 10.3389/fphar.2016.00305
26. European Commission (2012). Process on Corporate Social Responsibility in the Field of Pharmaceuticals Platform on Access to Medicines in Europe Working Group on Mechanism of Coordinated Access to Orphan Medicinal Products (MoCA-OMP)-TRANSPARENT VALUE FARAMEWORK.
27. European Commission (2017). Commission Expert Group on Safe and Timely Access to Medicines for Patients 'STAMP'. Available online at: https://ec.europa. eu/health/documents/pharmaceutical-committee/stamp_en
28. European Commission Public Health (2016). Public Consultation on Strengthening EU Cooperation on Health Technology Assessment (HTA). Available online at: https://ec.europa.eu/health/technology_assessment/consultations/ cooperation_hta_en
29. European Medicines Agency (2014). Adaptive Pathways to Patients: Report on the Initial Experience of the Pilot Project. Available online at: http://www.ema. europa.eu/docs/en_GB/document_library/Report/2014/12/WC500179560.pdf
30. European Medicines Agency (2016). Final Report on the Adaptive Pathways Pilot. Available online at: http://www.ema.europa.eu/docs/en_GB/document_ library/Report/2016/08/WC500211526.pdf
31. European Medicines Agency (2017). Conditional Marketing Authorisation, Report of Ten Years of Experience at the European Medicines Agency. Available online at: http://www.ema.europa.eu/docs/en_GB/document_library/Report/ 2017/01/WC500219991.pdf
32. European Medicines Agency -PRIME (2017). Priority Medicines. Available online at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/ general_content_000660.jsp&mid=WC0b01ac05809f8439
33. Experts in CML (2013). The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 121, 4439-4442. doi:10.1182/blood-2013-03-490003.
34. Ferguson, J. S., Summerhayes, M., Masters, S., Schey, S., and Smith, I. E. (2000). New treatments for advanced cancer: an approach to prioritization. Br. J. Cancer 83, 1268-1273. doi: 10.1054/bjoc.2000.1406
35. Ferrario, A., and Kanavos, P. (2013). Managed Entry Agreements for Pharmaceuticals: The European experience: LSE. Available online at: http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/mea_report_en.pdf
36. Ferrario, A., and Kanavos, P. (2015). Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden. Soc. Sci. Med. 124, 39-47. doi: 10.1016/j.socscimed.2014.11.003
37. Forslund, T., Raaschou, P., Hjemdahl, P., Krakau, I., and Wettermark, B. (2011). Usage, risk, and benefit of weight-loss drugs in primary care. J. Obes. 2011:459263. doi: 10.1155/2011/459263
38. Forslund, T., Wettermark, B., and Hjemdahl, P. (2016). Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation. Eur. J. Clin. Pharmacol. 72, 329-338. doi: 10.1007/s00228-015-1983-z
39. Gagnon,M. A. (2015). New drug pricing: does it make any sense? Prescrire. Int. 24, 192-195.
40. Garattini, L., and Curto, A. (2016). Performance-based agreements in Italy: 'Trendy outcomes' or mere illusions? Pharm. Econ. 34, 967-969. doi: 10.1007/s40273-016-0420-1
41. Garattini, S., Bertele, V., Godman, B., Haycox, A., Wettermark, B., and Gustafsson, L. L. (2008). Enhancing the rational use of new medicines across European health care systems. Eur. J. Clin. Pharmacol. 64, 1137-1138. doi: 10.1007/s00228-008-0537-z
42. Garattini, S., Gøtzsche, P. C., Jefferson, T., Laporte, J. R., Lexchin, J., Light, D. W., et al. (2016). European Public Health Alliance (EPHA) Briefing: Will Fast Track Medicines Approval Improve Affordability? Letter to Prof.Rasi and Dr. Eichler. Available online at: http://epha.org/scientists-voice-concerns-about-adaptive-pathways/
43. Garuoliene, K., Godman, B., Gulbinovic, J., Schiffers, K., and Wettermark, B. (2016). Differences in utilization rates between commercial and administrative databases: implications for future health-economic and cross-national studies. Expert Rev. Pharmacoecon. Outcomes Res. 16, 149-152. doi: 10.1586/14737167.2016.1158649
44. Ghinea, N., Kerridge, I., and Lipworth, W. (2015). If We Don't Talk About Value, Cancer Drugs will Become Terminal for Health Systems. 26/07/2015. Available online at: http://theconversation.com/if-we-dont-talk-about-valuecancer-drugs-will-become-terminal-for-health-systems-44072
45. Godman, B., Baker, A., Leporowski, A., Morton, A., Baumgärtel, C., Bochenek, T., et al. (2017). Initiatives to increase the prescribing of low cost generics; the case of Scotland in the international context. Med. Res. Archives 5, 1-34. doi: 10.18103/mra.v5i3.1071
46. Godman, B., Finlayson, A. E., Cheema, P. K., Zebedin-Brandl, E., Gutierrez-Ibarluzea, I., Jones, J., et al. (2013b). Personalizing health care: feasibility and future implications. BMC Med. 11:179. doi: 10.1186/1741-7015-11-179
47. Godman, B., Frost, I., Harrington, R., and Finlayson, A. E. (2016b). Personalising medicine: feasibility and future implications from a payers' perspective. J. Rare Dis. Res. Treat 1, 61-65.
48. Godman, B., Malmstrom, R. E., Diogene, E., Gray, A., Jayathissa, S., Timoney, A., et al. (2015). Are new models needed to optimize the utilisation of new medicines to sustain healthcare systems? Expert Rev. Clin. Pharmacol. 8, 77-94. doi: 10.1586/17512433.2015.990380
49. Godman, B., Malmstrom, R. E., Diogene, E., Jayathissa, S., McTaggart, S., Cars, T., et al. (2014). Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimise the utilisation of new drugs. Front. Pharmacol. 5:109. doi: 10.3389/fphar.2014.00109
50. Godman, B., Shrank, W., Andersen, M., Berg, C., Bishop, I., Burkhardt, T., et al. (2010). Policies to enhance prescribing efficiency in Europe: findings and future implications. Front. Pharmacol. 1:141. doi: 10.3389/fphar.2010.00141
51. Godman, B., Suh, H. S., Finlayson, A., Bennie, M., and Gustafsson, L. (2013a). Ongoing measures to enhance prescribing efficiency across Europe: implications for other countries. J. Health Tech. Assess. 1, 27-42.
52. Godman, B., Oortwijn, W., de Waure, C., Mosca, I., Puggina, A., Specchia, M. L., et al., (2016a). Links Between Pharmaceutical R&D Models and Access to Affordable Medicines. A Study for the ENVI COMMITTEE. Available online at: http://www.europarl.europa.eu/RegData/etudes/STUD/ 2016/587321/IPOL_STU(2016)587321_EN.pdf
53. Grössmann, N., and Wild, C. (2017). Between January 2009 and April 2016, 134 novel anticancer therapies were approved: what is the level of knowledge concerning the clinical benefit at the time of approval? ESMO Open 1:e000125. doi: 10.1136/esmoopen-2016-000125
54. Guerra-Júnior, A. A., Pires de Lemos, L. L., Godman, B., Bennie, M., Osoriode-Castro, C. G. S., Alvares, J., et al. (2017). Health technology performance assessment: real-world evidence for public healthcare sustainability. Int. J. Technol. Assess. Health Care. doi: 10.1017/S0266462317000423. [Epub ahead of print].
55. Hawkes, N. (2016a). Specialists attack drug agency's fast track approval scheme. Br. Med. J. 353:i3060. doi: 10.1136/bmj.i3060
56. Hawkes, N. (2016b). German body calls for pause in European plan for fast track drug approval. Br. Med. J. 354:i4479. doi: 10.1136/bmj.i4479
57. Haycox, A. (2016). Why Cancer? PharmacoEconomics 34, 625-627. doi: 10.1007/s40273-016-0413-0
58. Heads of Medicines Agencies (2007). Availability of Human Medicinal Products. Report of Task Force of HMAMG. Available online at: http://www.hma.eu/
59. Hill, A., Redd, C., Gotham, D., Erbacher, I., Meldrum, J., and Harada, R. (2017). Estimated generic prices of cancer medicines deemed costineffective in England: a cost estimation analysis. BMJ Open 7:e011965. doi: 10.1136/bmjopen-2016-011965
60. Hosseinpoor, A. R., Bergen, N., Koller, T., Prasad, A., Schlotheuber, A., Valentine, N., et al. (2014). Equity-oriented monitoring in the context of universal health coverage. PLoS Med. 11:e1001727. doi: 10.1371/journal.pmed.1001727
61. Howard, D. H., Berndt, E. R., and Conti, R. M. (2015). Pricing in the Market for Anticancer Drugs. J. Econ. Perspect. 29, 139-162. doi: 10.1257/jep.29.1.139
62. Hughes-Wilson,W., Palma, A., Schuurman, A., and Simoens, S. (2012). Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orphanet J. Rare Dis. 7:74. doi: 10.1186/1750-1172-7-74
63. Irwin, J., and Peacock, S. (2015). Multi-Criteria decision analysis: an emerging alternative for assessing the value of orphan medicinal products. Regulatory Rapporteur 12, 12-15.
64. Joint Briefing Paper (2015). "Adaptive licensing" or "Adaptive Pathways". Deregulation Under the Guise of Earlier Access. Brussels: International Society of Drug Bulletins, Medicines in Europe Forum, Nordic Cochrane Centre. Available online at: http://www.isdbweb.org/en/publications/view/adaptivelicensing-or-adaptive-pathways-deregulation-under-the-guise-of-earlieraccess
65. Joint Press Release (2016). EMA's Report on Adaptive Pathways: Little Data and TooMuch Ado About Nothing. Brussels: International Society of Drug Bulletins, Medicines in Europe Forum,Nordic Cochrane Centre. 31 August Press Release. Available online at: www.isdbweb.org/publications/download/213
66. Joint response to EMA public consultation (2015). A PRIME Example of How EMA is Pushing for Accelerated Market Approvals, But At What Cost for Patients? Available online at: http://www.isdbweb.org/en/publications/view/aprime-example-of-how-ema-is-pushing-for-accelerated-market-approvalsbut-at-what-cost-for-patients
67. Joppi, R., Gerardi, C., Bertele, V., and Garattini, S. (2016). Letting post-marketing bridge the evidence gap: the case of orphan drugs. Br. Med. J. 353:i2978. doi: 10.1136/bmj.i2978
68. Kamusheva, M., Stoimenova, A., Doneva, M., Zlatareva, A., and Petrova, G. (2013). A cross country comparison of reimbursed orphan medicines in Bulgaria, Greece and Romania. Biotechnol. Biotechnol. Equip. 27, 4186-4192. doi: 10.5504/BBEQ.2013.0066
69. Kanavos, P., Vandoros, S., Irwin, R., Nicod, E., and Casson, M. (2011). Differences in Costs of and Access to Pharmaceutical Products in the EU. European Parliament and Directorate-General for Internal Policies. Available online at: http://www.europarl.europa.eu/activities/committees/studies.do? language=EN
70. Kantarjian, H. M., Fojo, T., Mathisen, M., and Zwelling, L. A. (2013). Cancer drugs in the United States: Justum Pretium - the just price. J. Clin. Oncol. 31, 3600-3604. doi: 10.1200/JCO.2013.49.1845
71. Kaplan,W.,Wirtz, V. J.,Mantel-Teeuwisse, A., Stolk, P., Duthey, B., Laing, R., et al. (2013). Priority Medicines for Europe and the World. Update. Geneva: World Health Organisation. Available online at: http://www.who.int/medicines/areas/ priority_medicines/MasterDocJune28_FINAL_Web.pdf
72. Keeney, R. L. and Raiffa, H. (1993). Decisions with Multiple Objectives: Preferences and Value Trade-Offs. Cambridge: Cambridge University Press. Available online at: https://www.ispor.org/Multi-Criteria-Decision-Analysis-guideline. pdf
73. Kostic, M., Djakovic, L., Sujic, R., Godman, B., and Jankovic, S. M. (2017). Inflammatory Bowel Diseases (Crohn's Disease and Ulcerative Colitis): cost of Treatment in Serbia and the Implications. Appl. Health Econ. Health Policy 15, 85-93. doi: 10.1007/s40258-016-0272-z
74. Leopold, C., Vogler, S., Habl, C., Mantel-Teeuwisse, A. K., and Espin, J. (2013). Personalised medicine as a challenge for public pricing and reimbursement authorities-A survey among 27 European countries on the example of trastuzumab. Health Policy 113, 313-322. doi: 10.1016/j.healthpol.2013.09.018
75. Leopold, C., Vogler, S., Mantel-Teeuwisse, A. K., de Joncheere, K., Leufkens, H. G., and Laing, R. (2012). Differences in external price referencing in Europe: a descriptive overview. Health Policy 104, 50-60. doi: 10.1016/j.healthpol.2011.09.008
76. Mailankody, S., and Prasad, V. (2015). Five Years of Cancer Drug Approvals: innovation, efficacy, and costs. JAMA Oncol. 1, 539-540. doi: 10.1001/jamaoncol.2015.0373
77. Malmstrom, R. E., Godman, B. B., Diogene, E., Baumgartel, C., Bennie, M., Bishop, I., et al. (2013). Dabigatran -a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Front. Pharmacol. 4:39. doi: 10.3389/fphar.2013.00039
78. Matrix Insight (2012). Study on the Availability of Medicinal Products for Human Use. Available online at: http://ehtpa.eu/pdf/Matrix_report.pdf
79. Matusewicz, W., Godman, B., Pedersen, H. B., Furst, J., Mack, A., Selke, G., et al. (2015). Improving the managed introduction of new medicines: sharing experiences to aid authorities across Europe. Expert Rev. Pharmacoecon. Outcomes Res. 15, 755-758. doi: 10.1586/14737167.2015.1085803
80. Medicines and Healthcare Products Regulatory Agency (2016). Apply for the Early Access to Medicines Scheme (EAMS). GOV.UK. (Update of 20 May 2016). Available online at: https://www.gov.uk/guidance/apply-for-the-early-accessto-medicines-scheme-eams
81. Meyer, F. (2015). Sowing the SEEDs for HTA advice. Regul. Rapporteur 12, 10-11.
82. Moseley, J. (2015). Parallel EMA-HTA advice: past, present, and future. Regul. Rapporteur 12, 7-9
83. Motola, D., De Ponti, F., Poluzzi, E., Martini, N., Rossi, P., Silvani, M. C., et al. (2006). An update on the first decade of the European centralized procedure: how many innovative drugs? Br. J. Clin. Pharmacol. 62, 610-616. doi: 10.1111/j.1365-2125.2006.02700.x
84. Natsis, Y. (2016). Will Fast-Tracking Medicines Improve Affordability? Briefing Paper. European Public Health Alliance. Available online at: http://epha. org/wp-content/uploads/2016/05/Will-fast-tracking-for-new-medicinesimprove-affordability-formatted-5.pdf
85. Oliver, A. (2004). Equity of access to health care: outlining the foundation for action. J. Epidemiol. Community Health 58, 655-658. doi: 10.1136/jech.2003.017731
86. Paris, V., and Belloni, A. (2013). Value in Pharmaceutical Pricing. OECD Health Working Papers, No. 63: OECD.
87. Parkinson, B., Sermet, C., Clement, F., Crausaz, S., Godman, B., Garner, S., et al. (2015). Disinvestment and value-based purchasing strategies for pharmaceuticals: an international review. PharmacoEconomics 33, 905-924. doi: 10.1007/s40273-015-0293-8
88. Permanand, G., and Pedersen, H. (2015). Managing new premiumpriced medicines in Europe. J. Pharm. Policy Pract. 8(Suppl. 1):K2. doi: 10.1186/2052-3211-8-S1-K2
89. Pharma DiplomacyWorking Group. (2016). Principles for Collaborative, Mutually Acceptable Drug Pricing. Meteos.
90. Prasad, V., Wang, R., Afifi, S. H., and Mailankody, S. (2017). The rising price of cancer drugs- a new old problem? JAMA Oncol. 3, 277-278. doi: 10.1001/jamaoncol.2016.4275
91. Prescrire Editorial (2016). New drugs, new indications in 2015: little progress, and threats to access to quality healthcare for all. Rev. Prescrire 36, 133-137.
92. Putrik, P., Ramiro, S., Kvien, T. K., Sokka, T., Pavlova, M., Uhlig, T., et al. (2014). Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann. Rheum. Dis. 73, 198-206. doi: 10.1136/annrheumdis-2012-202603
93. Rasi, G., and Eicher, H. G. (2016). Reply to Prof. Silvio Garattini et al. 16 June. Available online at: http://www.ema.europa.eu/docs/en_GB/document_ library/Other/2016/06/WC500208968.pdf
94. Rawls, J. A. (1971). Theory of Justice. Cambridge, MA: The Belknap Press of Harvard University Press.
95. Salas-Vega, S., Iliopoulos, O., and Mossialos, E. (2017). Assessment of overall survival, quality of life, and safety benefits associated with new cancer medicines. JAMA Oncol. 3, 382-390. doi: 10.1001/jamaoncol.2016.4166
96. Schuurman, A. (2008). Assessment for reimbursement: Collaboration at EU-level, the MEDEV-experiment. Eurohealth 14, 33-34.
97. Sen, A. (2010). The Idea of Justice. London.
98. Shah-Manek, B., Galanto, J. S., Nguyen, H., and Ignoffo, R. (2017). Value frameworks for the patient-provider interaction: a comparison of the ASCO value framework versus NCCN evidence blocks in determining value in oncology. J. Manag. Care Spec. Pharm. 23(6-a Suppl), S13-S20. doi: 10.18553/jmcp.2017.23.6-a.s13
99. Simoens, S. (2010). How to assess the value of medicines? Front. Pharmacol. 1:115. doi: 10.3389/fphar.2010.00115
100. Simoens, S., Picavet, E., Dooms, M., Cassiman, D., and Morel, T. (2013). Costeffectiveness assessment of orphan drugs: a scientific and political conundrum. Appl. Health Econ. Health Policy 11, 1-3. doi: 10.1007/s40258-012-0004-y
101. Sullivan, S. D., Mduskepf, J. A., Augustovsku, F., Caro, J. J., Lee, K. M., Minchin, M., et al. (2014). ISPOR Task Force Report. Budget Impact Analysis - Principles of good practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health 17, 5-14. doi: 10.1016/j.jval.2013.08.2291
102. Tefferi, A., Kantarjian, H., Rajkumar, S. V., Baker, L. H., Abkowitz, J. L., Adamson, J. W., et al. (2015). In: support of a patient-driven initiative and petition to lower the high price of cancer drugs. Mayo Clin. Proc. 90, 996-1000. doi: 10.1016/j.mayocp.2015.06.001
103. Troncoso, A., and Diogene, E. (2014). Dabigatran and rivaroxaban prescription for atrial fibrillation in Catalonia, Spain: the need to manage the introduction of new drugs. Eur. J. Clin. Pharmacol. 70, 249-250. doi: 10.1007/s00228-013-1593-6
104. UK (2016). Accelerated Access Review: Final Report. Review of InnovativeMedicines and Medical Technologies. An independently chaired report, supported by the Wellcome Trust. Available online at: https://www.gov.uk/government/uploads/ system/uploads/attachment_data/file/565072/AAR_final.pdf
105. UK (2017). Early Access toMedicines Scheme (EAMS) Scientific Opinion: Raxone to Treat the Decline of Respiratory Function in Patients with Duchenne Muscular Dystrophy. Available online at: https://www.gov.uk/government/publications/ early-access-to-medicines-scheme-eams-scientific-opinion-raxone-to-treatthe-decline-of-respiratory-function-in-patients-with-duchenne-musculardys
106. Vella Bonanno, P. (2003). TheManaged Entry of New Drugs into a National Health Service - A Case Study for Malta. PhD Dissertation. Aberdeen: The Robert Gordon University.
107. Vella Bonanno, P. (2010). TheManaged Entry of New Drugs into a National Health Service - A Case Study for Malta, Prior to its Becoming a Member State of the European Union. Saarbrücken: LAP Lambert Academic Publishing, 103-105.
108. Vivot, A., Jacot, J., Zeitoun, J. D., Ravaud, P., Crequit, P., and Porcher, R. (2017). Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000-2015. Ann. Oncol. 28, 1111-1116. doi: 10.1093/annonc/mdx053
109. Vogler, S. (2008). PPRI Report. Available online at: http://whocc.goeg.at/ Publications/Articles
110. Vogler, S., Zimmermann, N., and Babar, Z. U. (2017). Price comparison of highcost originator medicines in European countries. Exp. Rev. Pharmacoecon. Outcomes Res. 17, 221-230. doi: 10.1080/14737167.2016.1223543
111. Vogler, S., Zimmermann, N., and Habimana, K. (2014). Study of the Policy Mix for Reimbursement of Medicinal Products. Available online at: http://whocc.goeg. at/Literaturliste/Dokumente/BooksReports/Vogler_Zimmerman_PolicyMix_ Final_Report.pdf
112. Ward, D. J., Slade, A., Genus, T., Martino, O. I., and Stevens, A. J. (2014). How innovative are new drugs launched in the UK? A retrospective study of new drugs listed in the British National Formulary (BNF) 2001-2012. Br. Med. J. 4:e006235. doi: 10.1136/bmjopen-2014-006235
113. Whitehead, M. (1991). The concepts and principles of equity and health. Health Promot. Int. 6, 217-228. doi: 10.1093/heapro/6.3.217
114. WHO CCPPRP (2017).WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies,WHOCC Glossary Preferred Terms. Available online at: http://whocc.goeg.at/Glossary/PreferredTerms (accessed 03.02.2017)
115. WHO (2001). How to Develop and Implement a National Drug Policy. Second Edition. Geneva: World Health Organization. Available online at: http://apps.who.int/medicinedocs/pdf/s2283e/s2283e.pdf
116. WHO (2015). Access to New Medicines in Europe: Technical Review of Policy Initiatives and Opportunities for Collaboration and Research. World Health Organization. Available online at: http://www.euro.who.int/en/health-topics/ Health-systems/medicines/publications2/2015/access-to-new-medicinesin-europe-technical-review-of-policy-initiatives-and-opportunities-forcollaboration-and-research.
117. Wild, C., Grossmann, N., Bonanno, P. V., Bucsics, A., Furst, J., Garuoliene, K., et al. (2016). Utilisation of the ESMO-MCBS in practice of HTA. Ann. Oncol. 27, 2134-2136. doi: 10.1093/annonc/mdw297
118. Woerkom, M., Piepenbrink, H., Godman, B., Metz, J., Campbell, S., Bennie, M., et al. (2012). Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications. J. Comp. Eff. Res. 1, 527-538. doi: 10.2217/cer.12.52